本文選題：SLE + ZBTB20　； 參考：《鄭州大學(xué)》2017年碩士論文

【摘要】：目的通過(guò)檢測(cè)鋅指蛋白ZBTB20在SLE患者B淋巴細(xì)胞中的表達(dá)情況并分析其與B細(xì)胞分化相關(guān)轉(zhuǎn)錄因子Blimp-1的關(guān)系,同時(shí)檢測(cè)狼瘡小鼠體內(nèi)ZBTB20的表達(dá),探究ZBTB20與SLE發(fā)病的相關(guān)性。方法(1)收集36例初診未經(jīng)治療的SLE患者和30例正常對(duì)照者外周血,分離外周血單個(gè)核細(xì)胞(PBMCs)。(2)采用磁珠分選法提取PBMCs中的CD19+B細(xì)胞,并用RT-PCR技術(shù)檢測(cè)CD19+B細(xì)胞中ZBTB20 m RNA與Blimp1 m RNA的表達(dá)水平(以-△△Ct值表示);采用流式細(xì)胞術(shù)檢測(cè)另一管PBMCs中B細(xì)胞亞群比例。(3)分析SLE患者外周血B細(xì)胞ZBTB20 m RNA的表達(dá)與B細(xì)胞亞群(包括CD19+B細(xì)胞,CD19-CD138+漿細(xì)胞)比例變化的關(guān)系,與Blimp1m RNA表達(dá)及實(shí)驗(yàn)室指標(biāo)抗ds-DNA抗體及免疫球蛋白Ig G的相關(guān)性。(4)狼瘡模型MRL/lpr小鼠、NZB/WF1小鼠培養(yǎng)至25-28周發(fā)病最嚴(yán)重期,并以同周期的正常對(duì)照C57BL/6小鼠作為對(duì)照,ELISA法檢測(cè)各組小鼠血清中抗ds-DNA抗體及免疫球蛋白Ig G水平。(5)取出小鼠的脾臟,淋巴結(jié),及胸腺,各組織其中一部分用于制備石蠟切片用于免疫組化檢測(cè)ZBTB20陽(yáng)性表達(dá),另一部分用于提取總RNA,RTPCR檢測(cè)ZBTB20 m RNA、Blimp-1 m RNA的表達(dá)水平(以-△△Ct值表示)。結(jié)果(1)ZBTB20 m RNA在SLE患者組外周血CD19+B細(xì)胞中的表達(dá)水平明顯高于正常對(duì)照組[(1.106±0.161)vs(2.527±0.355),P0.05];且SLE患者組Blimp1 m RNA的表達(dá)也明顯高于正常對(duì)照組[(1.106±0.161)vs(2.527±0.355),P0.05];(2)與對(duì)照組相比,SLE患者外周血B細(xì)胞亞群比例發(fā)生變化,其中CD19+B細(xì)胞比例降低[(4.87±3.49)vs(6.92±3.85),P0.05],而CD19-CD138+漿細(xì)胞比例和漿細(xì)胞/B細(xì)胞之間的比值均較對(duì)照組顯著增高[(0.49±0.41)vs(0.27±0.25),P0.05;(0.14±0.05)vs(0.03±0.03),P0.05],差異有統(tǒng)計(jì)學(xué)意義。(3)SLE患者B細(xì)胞ZBTB20 m RNA表達(dá)與CD19-CD138+漿細(xì)胞比例和漿細(xì)胞/B細(xì)胞比值呈正比[(r=0.165,P=0.028),(r=0.225,P=0.021)],與B細(xì)胞中Blimp1 m RNA的表達(dá)呈明顯的正相關(guān)性(r=0.112,P=0.039);SLE患者ZBTB20 m RNA的表達(dá)與血清中抗ds-DNA抗體,免疫球蛋白Ig G水平呈明顯正相關(guān)[(r=0.415,P=0.007),(r=0.507,P=0.005)]。(4)MRL/lpr小鼠、NZB/WF1小鼠處于發(fā)病嚴(yán)重期,脾臟、淋巴結(jié)及胸腺均有不同程度的腫大,血清中抗ds-DNA抗體,免疫球蛋白Ig G均較對(duì)照組增高[(5.27±3.79)vs(0.71±0.65),P0.05;(4.50±2.18)vs(0.71±0.65),P0.05)],[(12.35±7.74)vs(1.68±0.75),P0.05;(10.91±6.12)vs(1.68±0.75),P0.05)],差異有統(tǒng)計(jì)學(xué)意義,說(shuō)明構(gòu)建的小鼠模型符合實(shí)驗(yàn)預(yù)期。(5)MRL/lpr小鼠、NZB/WF1小鼠脾臟中ZBTB20 m RNA表達(dá)明顯高于正常對(duì)照組C57BL/6小鼠[(0.49±0.41)vs(0.27±0.25),P0.05;(0.14±0.05)vs(0.03±0.03),P0.05)],而模型組小鼠淋巴結(jié)及胸腺中ZBTB20 m RNA表達(dá)與對(duì)照組相比差異無(wú)統(tǒng)計(jì)學(xué)意義;且免疫組化的結(jié)果顯示,ZBTB20在狼瘡小鼠MRL/lpr小鼠、NZB/WF1小鼠脾臟中的表達(dá)與對(duì)照組相比陽(yáng)性表達(dá)率明顯增高[(21.3%vs5.2%),(40.2%vs5.2%)];而在淋巴結(jié)和胸腺中,ZBTB20的陽(yáng)性表達(dá)率與對(duì)照組相比差異無(wú)統(tǒng)計(jì)學(xué)意義。結(jié)論1.SLE患者外周血CD19+B細(xì)胞中ZBTB20 m RNA表達(dá)較對(duì)照組明顯增高,且同患者外周血CD19-CD138+漿細(xì)胞比例成正相關(guān),與血清中自身抗體水平呈正相關(guān),因此,ZBTB20可能與SLE發(fā)病有關(guān);2.SLE患者ZBTB20 m RNA的表達(dá)與同樣較對(duì)照組表達(dá)增高的B細(xì)胞分化關(guān)鍵調(diào)節(jié)因子Blimp1 m RNA表達(dá)呈正相關(guān),說(shuō)明ZBTB20參與SLE發(fā)病可能與B細(xì)胞異常分化有關(guān);3.狼瘡鼠模型實(shí)驗(yàn)進(jìn)一步說(shuō)明ZBTB20的表達(dá)與B細(xì)胞異常過(guò)度活化并分化為漿細(xì)胞分泌抗體有關(guān),ZBTB20可能是通過(guò)這一機(jī)制參與到SLE發(fā)病的。
[Abstract]:Objective to detect the expression of zinc finger protein ZBTB20 in the B lymphocyte of patients with SLE and to analyze the relationship with B cell differentiation related transcription factor Blimp-1, and to detect the expression of ZBTB20 in lupus mice, and to explore the correlation between ZBTB20 and SLE. Methods (1) 36 cases of early diagnosis of untreated SLE patients and 30 normal controls were collected. Peripheral blood, isolated peripheral blood mononuclear cells (PBMCs). (2) the CD19+B cells in PBMCs were extracted by magnetic bead sorting, and the expression level of ZBTB20 m RNA and Blimp1 m RNA in CD19+B cells was detected by RT-PCR technique (expressed in the value of delta delta Ct), and the proportion of the subgroup in the other tube was detected by flow cytometry. (3) analysis of the peripheral blood of the patients. The relationship between the expression of ZBTB20 m RNA and the proportion of B cell subsets, including CD19+B cells, CD19-CD138+ plasma cells, and the correlation between the expression of Blimp1m RNA and the anti ds-DNA antibody and immunoglobulin Ig G in the laboratory. (4) lupus model MRL/lpr mice were cultured to the most severe period of the onset of the 25-28 weeks, and the normal pairs of the same cycle were in the same cycle. The anti ds-DNA antibody and immunoglobulin Ig G level in the serum of each group were detected by ELISA method. (5) the spleen, lymph nodes and thymus of mice were taken out and part of the tissues were used to prepare the paraffin section for immunohistochemical detection of ZBTB20 positive expression, and the other part was used to extract total RNA, and RTPCR to detect ZBTB20 m RNA, The expression level of Blimp-1 m RNA (with the value of delta delta Ct). Results (1) the expression level of ZBTB20 m RNA in the peripheral blood CD19+B cells of the patients with SLE was significantly higher than that of the normal control group [(1.106 + 0.161) vs (2.527 + 0.355), P0.05], and the expression of the SLE patients was significantly higher than that of the normal control group [(1.106 + 0.161) (2.527 + 0.355). 2) compared with the control group, the proportion of B cell subsets in peripheral blood of SLE patients was changed, and the proportion of CD19+B cells decreased [(4.87 + 3.49) vs (6.92 + 3.85), P0.05], and the ratio of CD19-CD138+ plasma cell ratio and plasma cell /B cell increased significantly [(0.49 + 0.41) vs (0.27 + 0.25), P0.05; (0.14 + 0.05) vs (0.03 + 0.03), P0.05], poor (3) the expression of ZBTB20 m RNA in B cells in SLE patients was proportional to the ratio of CD19-CD138+ pulp cells and the ratio of /B cells to plasma cells (r=0.165, P=0.028), and (r=0.225, P=0.021)). The level of pestig protein Ig G was obviously positive correlation [(r=0.415, P=0.007), (r=0.507, P=0.005)]. (4) NZB/WF1 mice were in severe stage of onset, the spleen, lymph nodes and thymus were enlarged in varying degrees, the anti ds-DNA antibodies in the serum and the G of immunoglobulin Ig G were higher than those of the control group [(5.27 + 3.79) vs (0.71 + 0.65), 4.50 + 2.18) (0.) 71 + 0.65), P0.05), [(12.35 + 7.74) vs (1.68 + 0.75), P0.05, (10.91 + 6.12) vs (1.68 + 0.75), P0.05)], the difference was statistically significant, indicating that the constructed mouse model was in conformity with the experimental expectation. (5) MRL/lpr mice, the expression of ZBTB20 m RNA in the spleen of NZB/WF1 mice was significantly higher than that of C57BL/6 mice in the normal control group [0.49 + 0.41) vs. .05) vs (0.03 + 0.03), P0.05)], and the expression of ZBTB20 m RNA in the lymph nodes and thymus of the model mice was no significant difference compared with the control group; and the immunohistochemical results showed that the expression rate of ZBTB20 in the spleen of lupus mice was significantly higher than that of the control group [(21.3%vs5.2%), (40.2%vs5.2%)). In the lymph nodes and thymus, the positive expression rate of ZBTB20 was not statistically significant compared with the control group. Conclusion the expression of ZBTB20 m RNA in the peripheral blood CD19+B cells of 1.SLE patients was significantly higher than that of the control group, and it was positively correlated with the proportion of CD19-CD138+ plasma cells in peripheral blood, and was positively correlated with the level of autoantibodies in the serum. Therefore, ZBTB20 could be found. The expression of ZBTB20 m RNA in patients with 2.SLE was also positively correlated with the RNA expression of Blimp1 m, a key regulator of B cell differentiation in the control group, indicating that ZBTB20 participation in SLE may be related to the abnormal differentiation of B cells. 3. the 3. lupus rat model experiment further indicated that the expression of ZBTB20 and the abnormal activation of the cells were abnormal. ZBTB20 may be involved in the pathogenesis of SLE through differentiation into plasma cells secreting antibodies.
【學(xué)位授予單位】：鄭州大學(xué)
【學(xué)位級(jí)別】：碩士
【學(xué)位授予年份】：2017
【分類號(hào)】：R593.241

【相似文獻(xiàn)】

相關(guān)期刊論文 前10條

1 王強(qiáng);李晶;房俊;;B細(xì)胞及永生B細(xì)胞在傳染性單核細(xì)胞增多癥患兒中的動(dòng)態(tài)變化[J];實(shí)用兒科臨床雜志;2008年22期

2 林東方;張文;趙巖;;B細(xì)胞在原發(fā)性干燥綜合征中的作用[J];中華臨床免疫和變態(tài)反應(yīng)雜志;2009年03期

3 葉向軍;彭來(lái)君;施麗華;;不典型B細(xì)胞幼淋巴細(xì)胞白血病1例[J];臨床血液學(xué)雜志;2010年05期

4 劉克洲;;傳染性單核細(xì)胞增多癥周圍血中的T和B細(xì)胞[J];國(guó)外醫(yī)學(xué)參考資料(流行病學(xué)傳染病學(xué)分冊(cè));1975年01期

5 金天如;;傳染性單核細(xì)胞增多癥患者的B細(xì)胞減少癥[J];國(guó)外醫(yī)學(xué)(免疫學(xué)分冊(cè));1982年06期

6 張鐘儒;;用抗胸腺細(xì)胞球蛋白治療B細(xì)胞慢性淋巴細(xì)胞性白血病骨髓再生不良[J];國(guó)外醫(yī)學(xué)(腫瘤學(xué)分冊(cè));1992年04期

7 姚仁南;腫瘤壞死因子和淋巴細(xì)胞毒素對(duì)絲裂原激活的B細(xì)胞慢性淋巴細(xì)胞白血病細(xì)胞的不均一增殖作用[J];國(guó)外醫(yī)學(xué)(輸血及血液學(xué)分冊(cè));1994年01期

8 編輯部;;免疫療法有望治愈復(fù)發(fā)性B細(xì)胞急性淋巴細(xì)胞白血病[J];轉(zhuǎn)化醫(yī)學(xué)雜志;2013年02期

9 于力;汪月增;;非何杰金氏淋巴瘤患者病變組織和外周血克隆性B細(xì)胞測(cè)定的臨床意義[J];中國(guó)人民解放軍軍醫(yī)進(jìn)修學(xué)院學(xué)報(bào);1991年01期

10 勇威本;;B細(xì)胞慢性淋巴細(xì)胞白血病/小淋巴細(xì)胞淋巴瘤治療現(xiàn)狀[J];世界臨床藥物;2008年08期

相關(guān)會(huì)議論文 前10條

1 吳銘;孫雄飛;徐肇明;張新友;陳曉琳;林海清;文鴻光;孫璇;宋通微;李富榮;王興根;;基于細(xì)胞表型異常的流式細(xì)胞術(shù)檢測(cè)急性前體B細(xì)胞白血病微小殘留病[A];中華醫(yī)學(xué)會(huì)第八次全國(guó)血液學(xué)學(xué)術(shù)會(huì)議論文匯編[C];2004年

2 趙陽(yáng);張風(fēng)肖;;可溶性B細(xì)胞激活因子在原發(fā)性干燥綜合征的表達(dá)及其在致病中作用的研究[A];第17次全國(guó)風(fēng)濕病學(xué)學(xué)術(shù)會(huì)議論文集[C];2012年

3 徐衛(wèi);易樹(shù)華;李建勇;邱錄貴;;中國(guó)B細(xì)胞慢性淋巴增殖性疾病診斷專家共識(shí)(2013版)[A];中國(guó)腫瘤內(nèi)科進(jìn)展 中國(guó)腫瘤醫(yī)師教育（2014）[C];2014年

4 黃前榮;高曉明;;鈣網(wǎng)蛋白活化B細(xì)胞的分子機(jī)制研究[A];第六屆全國(guó)免疫學(xué)學(xué)術(shù)大會(huì)論文集[C];2008年

5 雷中勁;張軍紅;;B細(xì)胞激活因子在ITP患兒中表達(dá)的變化與意義[A];中華醫(yī)學(xué)會(huì)第十七次全國(guó)兒科學(xué)術(shù)大會(huì)論文匯編（下冊(cè)）[C];2012年

6 石群立;安曉靜;張正祥;馬捷;汪春年;;T淋巴母細(xì)胞淋巴瘤異常表達(dá)B細(xì)胞相關(guān)抗體-CD79a[A];第十一屆中國(guó)抗癌協(xié)會(huì)全國(guó)淋巴瘤學(xué)術(shù)大會(huì)教育論文集[C];2009年

7 郭穎P，

本文編號(hào)：1945753